These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 19891693)
1. The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours. Ferreira E; Bertagnolli AC; Cavalcanti MF; Schmitt FC; Cassali GD Vet Comp Oncol; 2009 Dec; 7(4):230-5. PubMed ID: 19891693 [TBL] [Abstract][Full Text] [Related]
2. Expression and significance of PTEN in canine mammary gland tumours. Qiu C; Lin D; Wang J; Wang L Res Vet Sci; 2008 Oct; 85(2):383-8. PubMed ID: 18082231 [TBL] [Abstract][Full Text] [Related]
3. Investigation of the local expression of the relaxin system in canine mammary tumours. Lamp O; Honscha KU; Jakob J; Lamp J; Schweizer S; Reischauer A; Gottschalk J; Hahn A; Ebert M; Rothemund S; Blaschzik S; Einspanier A Reprod Domest Anim; 2009 Jul; 44 Suppl 2():224-9. PubMed ID: 19754574 [TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic significance of CK19 in canine malignant mammary tumours. Gama A; Alves A; Schmitt F Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours. Santos A; Lopes C; Marques RM; Amorim I; Ribeiro J; Frias C; Vicente C; Gärtner F; de Matos A Vet J; 2011 Jul; 189(1):43-8. PubMed ID: 20598596 [TBL] [Abstract][Full Text] [Related]
6. Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53. Morris JS; Nixon C; King OJ; Morgan IM; Philbey AW Vet J; 2009 Mar; 179(3):422-9. PubMed ID: 18314357 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors. Chang CC; Tsai MH; Liao JW; Chan JP; Wong ML; Chang SC J Am Vet Med Assoc; 2009 Aug; 235(4):391-6. PubMed ID: 19681719 [TBL] [Abstract][Full Text] [Related]
8. Quantification of VEGF-C expression in canine mammary tumours. Qiu C; Lin DD; Wang HH; Qiao CH; Wang J; Zhang T Aust Vet J; 2008 Jul; 86(7):279-82. PubMed ID: 18616481 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. Gama A; Gärtner F; Alves A; Schmitt F Res Vet Sci; 2009 Dec; 87(3):432-7. PubMed ID: 19464036 [TBL] [Abstract][Full Text] [Related]
10. MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features. de Oliveira JT; Pinho SS; de Matos AJ; Hespanhol V; Reis CA; Gärtner F Vet J; 2009 Dec; 182(3):491-3. PubMed ID: 18948041 [TBL] [Abstract][Full Text] [Related]
11. The role of CD44 adhesion factor in canine mammary carcinomas. Madrazo J; García-Fernández RA; García-Iglesias MJ; Durán AJ; Espinosa J; Pérez-Martínez C Vet J; 2009 Jun; 180(3):371-6. PubMed ID: 18299241 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of progesterone and cellular proliferation in canine mammary tumours. Thuróczy J; Reisvaag GJ; Perge E; Tibold A; Szilágyi J; Balogh L J Comp Pathol; 2007; 137(2-3):122-9. PubMed ID: 17645888 [TBL] [Abstract][Full Text] [Related]
13. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Sorenmo KU; Kristiansen VM; Cofone MA; Shofer FS; Breen AM; Langeland M; Mongil CM; Grondahl AM; Teige J; Goldschmidt MH Vet Comp Oncol; 2009 Sep; 7(3):162-72. PubMed ID: 19691645 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical evaluation of MMP-2 and TIMP-2 in canine mammary tumours: a survival study. Santos A; Lopes C; Frias C; Amorim I; Vicente C; Gärtner F; Matos Ad Vet J; 2011 Dec; 190(3):396-402. PubMed ID: 21269852 [TBL] [Abstract][Full Text] [Related]
15. Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression. Pinho SS; Matos AJ; Lopes C; Marcos NT; Carvalheira J; Reis CA; Gärtner F BMC Cancer; 2007 Jul; 7():124. PubMed ID: 17617904 [TBL] [Abstract][Full Text] [Related]
16. Loss of p27 expression in canine mammary tumors and their metastases. Klopfleisch R; Schütze M; Gruber AD Res Vet Sci; 2010 Apr; 88(2):300-3. PubMed ID: 19748645 [TBL] [Abstract][Full Text] [Related]
17. Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival. Gama A; Paredes J; Gärtner F; Alves A; Schmitt F Vet J; 2008 Jul; 177(1):45-53. PubMed ID: 17631398 [TBL] [Abstract][Full Text] [Related]
18. E-cadherin expression in canine malignant mammary tumours: relationship to other clinico-pathological variables. Matos AJ; Lopes C; Carvalheira J; Santos M; Rutteman GR; Gärtner F J Comp Pathol; 2006; 134(2-3):182-9. PubMed ID: 16545841 [TBL] [Abstract][Full Text] [Related]
19. Estrogen receptors in canine mammary gland tumours. Sobczak-Filipiak M; Malicka E Pol J Vet Sci; 2002; 5(1):1-5. PubMed ID: 11944580 [TBL] [Abstract][Full Text] [Related]
20. Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. Hsu WL; Huang HM; Liao JW; Wong ML; Chang SC Vet J; 2009 Apr; 180(1):116-23. PubMed ID: 18061495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]